Medy-Tox (KRX: 086900)
Who is buying Medy-Tox?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩4.3bn ($3M) of Medy-Tox, the 121st largest foreign net sale among 1828 KOSDAQ stocks. Institutions net sold ₩0.1bn ($0M) and retail investors net bought ₩4.2bn ($3M) over the same window. Foreigners were net buyers on 8 of the 20 sessions.
Foreign investors hold 11.94% of Medy-Tox's listed shares (KRX ownership data as of Oct 13, 2026), down from 14.48% twenty sessions earlier and 8.38% a year ago.
The stock closed at ₩63,500 on Oct 13, 2026: -7.84% over 20 sessions, -47.43% year-to-date, -46.73% over one year. The 52-week range is ₩61,600 – ₩141,100.
At ₩63,500 the stock trades at 13.49× 12-month-forward consensus earnings (3 analysts), 12.31× on FY2027 estimates. The trailing P/E published by KRX is 26.78×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩63,500 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-10-12 | ₩64,100 | ₩-0.5bn | ₩-0.0bn | +₩0.5bn |
| 2026-10-08 | ₩65,900 | ₩-1.1bn | ₩-0.1bn | +₩1.1bn |
| 2026-10-07 | ₩67,500 | +₩0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-10-06 | ₩67,500 | +₩0.1bn | +₩0.0bn | ₩-0.2bn |
| 2026-10-02 | ₩66,600 | ₩-0.3bn | ₩-0.1bn | +₩0.4bn |
| 2026-10-01 | ₩67,400 | +₩0.1bn | +₩0.0bn | ₩-0.2bn |
| 2026-09-30 | ₩66,500 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-29 | ₩67,100 | ₩-0.7bn | ₩-0.0bn | +₩0.7bn |
| 2026-09-28 | ₩68,700 | +₩0.3bn | +₩0.1bn | ₩-0.4bn |
| 2026-09-23 | ₩67,400 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-22 | ₩67,300 | +₩0.1bn | ₩-0.1bn | ₩-0.1bn |
| 2026-09-21 | ₩68,100 | +₩0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-18 | ₩67,300 | ₩-1.0bn | +₩0.0bn | +₩0.9bn |
| 2026-09-17 | ₩67,600 | ₩-0.2bn | ₩-0.0bn | +₩0.3bn |
| 2026-09-16 | ₩67,800 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-15 | ₩68,700 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-09-14 | ₩68,800 | ₩-0.1bn | ₩-0.1bn | +₩0.2bn |
| 2026-09-11 | ₩69,600 | ₩-0.3bn | +₩0.5bn | ₩-0.2bn |
| 2026-09-10 | ₩69,400 | ₩-0.6bn | ₩-0.2bn | +₩0.7bn |
| 2026-09-09 | ₩68,900 | ₩-0.7bn | +₩0.3bn | +₩0.3bn |
| 2026-09-08 | ₩69,200 | ₩-0.4bn | ₩-0.0bn | +₩0.4bn |
| 2026-09-07 | ₩69,400 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-04 | ₩69,600 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-03 | ₩69,300 | ₩-1.8bn | ₩-0.2bn | +₩2.0bn |
| 2026-09-02 | ₩71,200 | +₩0.0bn | ₩-0.1bn | +₩0.0bn |
| 2026-09-01 | ₩73,000 | +₩1.3bn | +₩0.1bn | ₩-1.3bn |
| 2026-08-31 | ₩68,900 | ₩-1.1bn | +₩0.3bn | +₩0.8bn |
| 2026-08-28 | ₩71,100 | +₩0.8bn | +₩0.3bn | ₩-1.1bn |
| 2026-08-27 | ₩66,900 | ₩-1.2bn | ₩-0.3bn | +₩1.4bn |
| 2026-08-26 | ₩68,600 | +₩0.6bn | ₩-0.2bn | ₩-0.4bn |
| 2026-08-25 | ₩67,800 | ₩-0.3bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-24 | ₩67,400 | ₩-0.4bn | +₩0.2bn | +₩0.2bn |
| 2026-08-21 | ₩67,400 | ₩-2.1bn | ₩-0.2bn | +₩2.2bn |
| 2026-08-20 | ₩71,000 | ₩-0.1bn | +₩0.2bn | ₩-0.1bn |
| 2026-08-19 | ₩68,400 | ₩-1.4bn | ₩-0.0bn | +₩1.4bn |
| 2026-08-18 | ₩71,500 | ₩-1.9bn | ₩-0.2bn | +₩2.1bn |
| 2026-08-14 | ₩76,900 | +₩0.0bn | ₩-0.2bn | +₩0.2bn |
| 2026-08-13 | ₩76,800 | +₩0.4bn | ₩-0.6bn | +₩0.2bn |
| 2026-08-12 | ₩77,300 | ₩-0.9bn | ₩-0.1bn | +₩1.0bn |
| 2026-08-11 | ₩78,000 | ₩-0.5bn | +₩0.0bn | +₩0.4bn |
| 2026-08-10 | ₩80,900 | ₩-0.2bn | ₩-0.1bn | +₩0.3bn |
| 2026-08-07 | ₩79,800 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-06 | ₩79,000 | +₩0.3bn | ₩-0.0bn | ₩-0.3bn |
| 2026-08-05 | ₩76,800 | ₩-0.7bn | +₩0.1bn | +₩0.2bn |
| 2026-08-04 | ₩76,900 | +₩0.6bn | +₩0.1bn | ₩-0.6bn |
| 2026-08-03 | ₩72,000 | +₩0.5bn | ₩-0.6bn | +₩0.1bn |
| 2026-07-31 | ₩72,000 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-07-30 | ₩70,800 | +₩0.5bn | +₩0.2bn | ₩-0.5bn |
| 2026-07-29 | ₩68,200 | +₩0.2bn | +₩0.4bn | ₩-0.7bn |
| 2026-07-28 | ₩71,300 | +₩0.6bn | ₩-0.1bn | ₩-0.6bn |
| 2026-07-27 | ₩73,500 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-07-24 | ₩71,000 | +₩0.5bn | ₩-0.0bn | ₩-0.4bn |
| 2026-07-23 | ₩71,500 | +₩0.5bn | +₩0.1bn | ₩-0.5bn |
| 2026-07-22 | ₩68,300 | +₩0.0bn | ₩-0.3bn | +₩0.3bn |
| 2026-07-21 | ₩69,000 | +₩0.2bn | +₩0.2bn | ₩-0.3bn |
| 2026-07-20 | ₩68,500 | +₩0.1bn | ₩-0.3bn | +₩0.2bn |
| 2026-07-16 | ₩71,600 | +₩0.0bn | +₩0.3bn | ₩-0.2bn |
| 2026-07-15 | ₩72,400 | +₩0.6bn | ₩-0.1bn | ₩-0.6bn |
| 2026-07-14 | ₩70,000 | ₩-0.4bn | +₩0.2bn | +₩0.1bn |
| 2026-07-13 | ₩71,500 | ₩-0.1bn | +₩0.5bn | ₩-0.4bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩0.1bn | +$0M | ₩-0.0bn | ₩-0.1bn |
| 5 days | ₩-1.3bn | $-1M | ₩-0.1bn | +₩1.4bn |
| 20 days | ₩-4.3bn | $-3M | ₩-0.1bn | +₩4.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Medy-Tox stock?
Over the last 5 sessions foreign investors net sold ₩1.3bn ($1M) of Medy-Tox; over 60 sessions they net sold ₩9.9bn ($7M); since Jan 1, 2026 they net bought ₩13.4bn ($10M). Over 20 sessions the stock is the 121st largest foreign net sale among 1828 KOSDAQ stocks.
How much of Medy-Tox do foreign investors own?
Foreign investors own 11.94% of Medy-Tox's shares as of Oct 13, 2026, versus 8.38% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.1bn ($0M) and retail investors net bought ₩4.2bn ($3M) of Medy-Tox. Retail investors have been absorbing what foreigners and institutions are selling.
Is Medy-Tox listed on KOSPI or KOSDAQ?
Medy-Tox (메디톡스) trades on KOSDAQ under KRX code 086900 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩221bn ($166M) | – | ₩17bn ($13M) | ₩10bn ($7M) |
| 2024 | ₩229bn ($171M) | +3.40% | ₩20bn ($15M) | ₩16bn ($12M) |
| 2025 | ₩247bn ($186M) | +8.20% | ₩17bn ($13M) | ₩16bn ($12M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.